BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia
To conduct a multicenter, randomized, placebo-controlled, double-blind, phase II study of BAY41-6551 (NCT01004445), an investigational drug–device combination of amikacin, formulated for inhalation, and a proprietary Pulmonary Drug Delivery System, for the treatment of Gram-negative pneumonia in mechanically ventilated patients.
Sixty-nine mechanically ventilated patients with Gram-negative pneumonia, a clinical pulmonary infection score ≥6, at risk for multidrug-resistant organisms, were randomized to BAY41-6551 400 mg every 12 h (q12h), 400 mg every 24 h (q24h) with aerosol placebo, or placebo q12h for 7–14 days, plus standard intravenous antibiotics. The combined primary endpoint was a tracheal aspirate amikacin maximum concentration ≥6,400 μg/mL (25 × 256 μg/mL reference minimum inhibitory concentration) and a ratio of area under the aspirate concentration–time curve (0–24 h) to minimum inhibitory concentration ≥100 on day 1.
The primary endpoint was achieved in 50% (6/12) and 16.7% (3/18) of patients in the q12h and q24h groups, respectively. Clinical cure rates, in the 48 patients getting ≥7 days of therapy, were 93.8% (15/16), 75.0% (12/16), and 87.5% (14/16) in the q12h, q24h, and placebo groups, respectively (p = 0.467). By the end of aerosol therapy, the mean number of antibiotics per patient per day was 0.9 in the q12h, 1.3 in the q24h, and 1.9 in the placebo groups, respectively (p = 0.02 for difference between groups). BAY41-6551 was well tolerated and attributed to two adverse events in one patient (mild bronchospasm).
BAY41-6551 400 mg q12h warrants further clinical evaluation.
KeywordsBAY41-6551 Gram-negative pneumonia Inhaled amikacin Tracheal concentrations Ventilator-associated pneumonia
- 15.Sader H, Jones N (2004) In vitro activity of amikacin tested against bacterial isolates from patients with pneumonia hospitalized in intensive care units. Commissioned report. JMI Laboratories, North LibertyGoogle Scholar
- 16.US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (1998) Guidance for industry: nosocomial pneumonia—developing antimicrobial drugs for treatment. http://www.fda.gov/ohrms/dockets/98fr/2571dft.pdf. Accessed 15 March 2011
- 21.Luyt CE, Eldon MA, Stass H, Gribben D, Corkery K, Chastre J (2011) Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with Gram-negative pneumonia and acute renal failure. J Aerosol Med Pulm Drug Deliv. doi:10.1089/jamp.2010.0860
- 22.Stass H, Corkery K, Gribben D, Eldon MA (2011) Pharmacokinetics and tolerability of BAY41-6551 in subjects with chronic kidney disease. J Aerosol Med Pulm Drug Deliv. doi:10.1089/jamp.2010.0859
- 25.EUCAST (2009) Aminoglycosides—EUCAST clinical MIC breakpoints 2009-06-15 (v 1.5). http://www.srga.org/eucastwt/MICTAB/MICaminoglycosides.html. Accessed 15 March 2011
- 28.Luyt CE, Clavel M, Guntupalli K, Johannigman J, Kennedy JI, Wood C, Corkery K, Gribben D, Chastre J (2009) Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care 13:R200PubMedCrossRefGoogle Scholar